Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186991 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT01186991 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 185 participants.
The verdict
NCT01186991, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).
Interventions
- DRUG Bevacizumab
- DRUG Paclitaxel
- DRUG Onartuzumab
- DRUG Bevacizumab Placebo
- DRUG Onartuzumab Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01186991
The ClinicalTrials.gov registry entry for NCT01186991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01186991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01186991 about?
NCT01186991 is a clinical study titled "Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer". This is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (MetMAb) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclit...
What is the current status of trial NCT01186991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2011-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01186991?
The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), Onartuzumab (DRUG), Bevacizumab Placebo (DRUG), Onartuzumab Placebo (DRUG).
Who is sponsoring clinical trial NCT01186991?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.